AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06642597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full dose PD
Description: Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
Study NCT05597124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio-Dance Fitness
Description: This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
Study NCT05597124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength, Flexibility & Balance
Description: This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
Study NCT05824728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101
Description: low-dose levetiracetam, 220 mg, extended release tablet
Study NCT06539442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versius Surgical System
Description: Urological minimal access surgery performed with Versius Surgical System
Study NCT04940546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Mode of administration: Intravenously
Study NCT04940546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Mode of administration: Intravenously
Study NCT04940546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Mode of administration: Orally
Study NCT04940546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Mode of administration: Intravenously
Study NCT05048355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Knee Mainstream Dynamic
Description: Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
Study NCT05413421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-944
Description: Oral, once daily, continuous
Study NCT05048355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive microprocessor controlled knee
Description: Any passive microprocessor controlled prosthetic knee on the market
Study NCT05464108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endosopists
Description: Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
Study NCT05508360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQdisc Nucleus Replacement System
Description: Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Study NCT05413421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
Description: Oral, 1000 mg once daily, continuous
Study NCT05413421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Description: Oral, 240 mg once daily, continuous
Study NCT04499131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
Study NCT05413421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa®) 300 mg tablets
Description: Oral, 600 mg twice daily, continuous
Study NCT05413421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Description: Oral, 160 mg once daily, continuous
Study NCT06019585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint inmmobilization
Description: After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
Study NCT06019585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage immovilization
Description: After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
Study NCT06345092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: addition of vitamin C to IPRF
Study NCT06345092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platelet rich fibrin
Description: injection of IPRF alone
Study NCT06345092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin
Description: injection of IPRF alone
Study NCT06664606 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education Program (PNE)
Description: The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
Study NCT06662942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: StrataMGT
Description: StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
Study NCT06662942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
Study NCT06666036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Community level enhancements
Study NCT05995600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug
Description: Clopidogrel ± other antiplatelet drug
Study NCT05995600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
Study NCT03845036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Diet plus Home-Based Exercise
Description: The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
Study NCT03845036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
Study NCT05620134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK08
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
Study NCT05620134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor
Study NCT05620134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: Multi-kinase inhibitor
Study NCT05149872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle relaxation
Description: Rocuronium will be used to induce partial paralysis
Study NCT05098704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel treatment
Description: 75 mg daily during 24 months
Study NCT05098704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg daily during 24 months
Study NCT06609512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral Tablet
Study NCT06665672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist worn vibro-acoustic device
Description: The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.
Study NCT06671457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some
Study NCT06671457 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryodevitalization
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Bronchoscopy
Description: Undergo standard of care robotic bronchoscopy with biopsy
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Biopsy
Description: Undergo standard of care robotic bronchoscopy with biopsy
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care surgical resection
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography
Study NCT06593106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tissue sample collection
Study NCT06593106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05764408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traxi® Panniculus Retractor
Description: traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
Study NCT06676670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real acupuncture
Description: Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.
Study NCT06676670 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo
Study NCT06681493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729 Tartrate injection
Description: Infusion, QD
Study NCT06681493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-4729 simulated injection
Description: Infusion, QD
Study NCT06680167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia (heavy bupivacaine 0.5%)
Description: 12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
Study NCT06680167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia (hyperbaric Prilocaine 2%)
Description: 60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
Study NCT05240599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training will be applied 3 times a day for 8 weeks.
Study NCT06680973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-Based Resistance Training
Description: Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks.
Study NCT06680973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based Resistance Training
Description: Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded.
Study NCT06681155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of plaque morphology, structure, and stability in non-culprit lesions
Description: Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
Study NCT06681090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
Description: The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
Study NCT06681090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Description: First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
Study NCT06680570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing
Description: Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life.
Study NCT06681545 — intervention group
Intervention type: OTHER
Intervention: one to one interviews and or focus groups
Description: one to one interviews and or focus groups
Study NCT05149872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reversal
Description: Sugamamdex will be used to reverse muscle relaxation
Study NCT06681532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars
Description: The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.
Study NCT06681532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars
Description: the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
Study NCT06706271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2000 IU of Vitamin D
Study NCT06707168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital palpation
Description: Digital palpation for IOP measurement
Study NCT06707168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cotton-tipped applicator (CTA)
Description: Cotton-tipped applicator (CTA) for IOP measurement
Study NCT06710795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MaxTack™ Motorized Fixation Device
Description: All subjects enrolled will receive the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
Study NCT04663061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical weight loss
Description: Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight